Background: Pyrazolones are the most common causes of selective nonsteroidal anti-inflammatory drug (NSAID) hypersensitivity. We studied a large group of patients with immediate and delayed selective responses to metamizole. Methods: Patients with suspicion of hypersensitivity to metamizole were evaluated. We verified acetylsalicylic acid tolerance and classified patients as immediate or delayed responders if they showed symptoms less or more than 24 h after metamizole administration. Skin tests were performed and if negative, a basophil activation test (BAT) was performed on immediate responders. If it was negative, we performed a drug provocation test (DPT) with metamizole. Results: A total of 137 patients were included: 132 reacted within 24 h (single NSAID-induced urticaria/angioedema/anaphylaxis; SNIUAA) and 5 after 24 h (single NSAID-induced delayed hypersensitivity reaction; SNIDHR). Most SNIUAA patients developed anaphylaxis (60.60%); for SNIDHR, maculopapular exanthema was the most frequent entity (60%). Skin testing was positive in 62.04% of all cases and BAT in 28% of the SNIUAA patients with negative skin tests. In 5.1% of the cases, DPT with metamizole was needed to establish the diagnosis. In 22.62% of the cases, diagnosis was established by consistent and unequivocal history of repeated allergic episodes in spite of a negative skin test and BAT. Conclusions: SNIUAA to metamizole is the most frequent type of selective NSAID hypersensitivity, with anaphylaxis being the most common clinical entity. It may occur within 1 h after drug intake. SNIDHR occurs in a very low percentage of cases. The low sensitivity of diagnostic tests may be due to incomplete characterization of the chemical structures of metamizole and its metabolites.

Keywords:
Basophil activation test, Drug provocation test, Metamizole, Selective hypersensitivity, Skin test
1.
Thong BY, Tan TC: Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 2011;71:684-700.
2.
Dona I, Blanca-Lopez N, Torres MJ, Garcia-Campos J, Garcia-Nunez I, Gomez F, et al: Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J Investig Allergol Clin Immunol 2012;22:363-371.
3.
Zambonino MA, Torres MJ, Munoz C, Requena G, Mayorga C, Posadas T, et al: Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflammatory drugs in children. Pediatr Allergy Immunol 2013;24:151-159.
4.
Antunez C, Martin E, Cornejo-Garcia JA, Blanca-Lopez N, R-Pena R, Mayorga C, et al: Immediate hypersensitivity reactions to penicillins and other betalactams. Curr Pharm Des 2006;12:3327-3333.
5.
Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al: Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 2013;68:1219-1232.
6.
Canto MG, Andreu I, Fernandez J, Blanca M: Selective immediate hypersensitivity reactions to NSAIDs. Curr Opin Allergy Clin Immunol 2009;9:293-297.
7.
Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, et al: IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003;111:882-888.
8.
Schneider CH, Kasper MF, de Weck AL, Rolli H, Angst BD: Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships. Allergy 1987;42:597-603.
9.
Blanca M, Perez E, Garcia JJ, Miranda A, Terrados S, Vega JM, et al: Angioedema and IgE antibodies to aspirin: a case report. Ann Allergy 1989;62:295-298.
10.
Harrer A, Lang R, Grims R, Braitsch M, Hawranek T, Aberer W, et al: Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. PLoS One 2010;5:e13707.
11.
Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al: Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002;109:155-161.
12.
Gomez E, Blanca-Lopez N, Salas M, Canto G, Campo P, Torres MJ, et al: Induction of accelerated reactions to amoxicillin by T-cell effector mechanisms. Ann Allergy Asthma Immunol 2013;110:267-273.
13.
Terrados S, Blanca M, Garcia J, Vega J, Torres MJ, Carmona MJ, et al: Nonimmediate reactions to betalactams: prevalence and role of the different penicillins. Allergy 1995;50:563-567.
14.
Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913-921.
15.
Jenkins C, Costello J, Hodge L: Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004;328:434.
16.
Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al: Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-1614.
17.
Sanak M, Gielicz A, Bochenek G, Kaszuba M, Nizankowska-Mogilnicka E, Szczeklik A: Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. J Allergy Clin Immunol 2011;127:1141.e2-1147.e2.
18.
Blanca-Lopez N, J Torres M, Dona I, Campo P, Rondon C, Seoane Reula ME, et al: Value of the clinical history in the diagnosis of urticaria/angioedema induced by NSAIDs with cross-intolerance. Clin Exp Allergy 2013;43:85-91.
19.
Dona I, Blanca-Lopez N, Torres MJ, Gomez F, Fernandez J, Zambonino MA, et al: NSAID-induced urticaria/angioedema does not evolve into chronic urticaria: a 12-year follow-up study. Allergy 2014;69:438-444.
20.
Dona I, Blanca-Lopez N, Cornejo-Garcia JA, Torres MJ, Laguna JJ, Fernandez J, et al: Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. Clin Exp Allergy 2011;41:86-95.
21.
Kowalski ML, Woszczek G, Bienkiewicz B, Mis M: Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998;28:1153-1158.
22.
Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P: General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy 2002;57:45-51.
23.
Gomez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, et al: Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. Clin Exp Allergy 2009;39:1217-1224.
24.
Ayuso P, Blanca-Lopez N, Dona I, Torres MJ, Gueant-Rodriguez RM, Canto G, et al: Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. Clin Exp Allergy 2013;43:1097-1109.
25.
Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, et al: Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. Allergy 2003;58:312-317.
26.
Gamboa P, Sanz ML, Caballero MR, Urrutia I, Antepara I, Esparza R, et al: The flow-cytometric determination of basophil activation induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is useful for in vitro diagnosis of the NSAID hypersensitivity syndrome. Clin Exp Allergy 2004;34:1448-1457.
27.
Sanz ML, Gamboa P, de Weck AL: A new combined test with flowcytometric basophil activation and determination of sulfidoleukotrienes is useful for in vitro diagnosis of hypersensitivity to aspirin and other nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005;136:58-72.
28.
Blanca M, Torres MJ, Garcia JJ, Romano A, Mayorga C, de Ramon E, et al: Natural evolution of skin test sensitivity in patients allergic to beta-lactam antibiotics. J Allergy Clin Immunol 1999;103:918-924.
29.
Fernandez TD, Torres MJ, Blanca-Lopez N, Rodriguez-Bada JL, Gomez E, Canto G, et al: Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. Allergy 2009;64:242-248.
30.
Ariza A, Fernandez TD, Dona I, Aranda A, Blanca-Lopez N, Melendez L, et al: Basophil activation after nonsteroidal anti-inflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs. Cytometry A 2014;85:400-407.
31.
Levy M, Zylber-Katz E, Rosenkranz B: Clinical pharmacokinetics of dipyrone and its metabolites. Clin Pharmacokinet 1995;28:216-234.
32.
Martinez C, Andreu I, Amo G, Miranda MA, Esguevillas G, Torres MJ, et al: Gender and functional CYP2C and NAT2 polymorphisms determine the metabolic profile of metamizole. Biochem Pharmacol 2014;92:457-466.
33.
Wessel JC, Matyja M, Neugebauer M, Kiefer H, Daldrup T, Tarbah FA, et al: Characterization of oxalic acid derivatives as new metabolites of metamizol (dipyrone) in incubated hen's egg and human. Eur J Pharm Sci 2006;28:15-25.
34.
Ozkaya-Bayazit E, Bayazit H, Ozarmagan G: Drug related clinical pattern in fixed drug eruption. Eur J Dermatol 2000;10:288-291.
35.
Gonzalo-Garijo MA, Perez-Calderon R, De Argila D, Rodriguez-Nevado I: Metamizole-induced acute generalized exanthematous pustulosis. Contact Dermatitis 2003;49:47-48.
36.
Borja JM, Galindo PA, Gomez E, Feo F: Delayed skin reactions to metamizol. Allergy 2003;58:84-85.
37.
Dalmau J, Serra-Baldrich E, Roe E, Peramiquel L, Alomar A: Use of patch test in fixed drug eruption due to metamizole (Nolotil). Contact Dermatitis 2006;54:127-128.
38.
Macias E, Ruiz A, Moreno E, Laffond E, Davila I, Lorente F: Usefulness of intradermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy 2007;62:1462-1464.
39.
Romano A, Torres MJ, Castells M, Sanz ML, Blanca M: Diagnosis and management of drug hypersensitivity reactions. J Allergy Clin Immunol 2011;127(3 suppl):S67-S73.
40.
Blanca M, Romano A, Torres MJ, Fernandez J, Mayorga C, Rodriguez J, et al: Update on the evaluation of hypersensitivity reactions to betalactams. Allergy 2009;64:183-193.
41.
Bircher AJ, Scherer Hofmeier K: Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol 2012;129:263-264.
42.
Agundez JA, Martinez C, Benitez J: Metabolism of aminopyrine and derivatives in man: in vivo study of monomorphic and polymorphic metabolic pathways. Xenobiotica 1995;25:417-427.
43.
Vlahov V, Badian M, Verho M, Bacracheva N: Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium. Eur J Clin Pharmacol 1990;38:61-65.
44.
Zhu D, Becker WM, Schulz KH, Schubeler K, Schlaak M: Detection of IgE antibodies specific for 1-phenyl-2,3-dimethyl-3-pyrazoline-5-one by RAST: a serological diagnostic method for sensitivity to pyrazoline drugs. Asian Pac J Allergy Immunol 1992;10:95-101.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.